This Month in JNM ================= **Cardiac stem cell tracking:** Zhang and Wu review the basic principles, current techniques, and future prospects for in vivo stem cell cardiovascular imaging.
***[Page 1916](http://jnm.snmjournals.org/lookup/volpage/48/1916?iss=12)*** **PET/CT in pediatric malignancies:** Federman and Feig offer the clinician's perspective on the status of functional/anatomic imaging in pediatric cancers and point to specific challenges, including the need for additional research and more refined protocols.
***[Page 1920](http://jnm.snmjournals.org/lookup/volpage/48/1920?iss=12)*** **PET/CT in non-CNS pediatric cancers:** Tatsumi and colleagues compare the accuracy and efficacy of PET/CT and conventional imaging in evaluating young patients with non–central nervous system malignancies.
***[Page 1923](http://jnm.snmjournals.org/lookup/volpage/48/1923?iss=12)*** ![Figure1](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F1.medium.gif) [Figure1](http://jnm.snmjournals.org/content/48/12/11A/F1) **PET/CT for Ewing tumors:** Gerth and colleagues assess the relative advantages of PET/CT and PET alone in staging and restaging patients with Ewing tumor, with additional findings on the ability of the hybrid technique to detect new lesions.
***[Page 1932](http://jnm.snmjournals.org/lookup/volpage/48/1932?iss=12)*** **18F-FDA PET in pheochromocytoma:** Timmers and colleagues report on patient studies designed to establish cutoff values for pathologic and physiologic adrenal gland tracer uptake in 6-18F-fluorodopamine PET localization of pheochromocytoma.
***[Page 1940](http://jnm.snmjournals.org/lookup/volpage/48/1940?iss=12)*** ![Figure2](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F2.medium.gif) [Figure2](http://jnm.snmjournals.org/content/48/12/11A/F2) **18F-FLT PET in gastric cancer:** Herrmann and colleagues evaluate the proliferation marker 18F-fluorothymidine for PET detection of gastric cancer and compare the resulting diagnostic accuracy with that of 18F-FDG PET.
***[Page 1945](http://jnm.snmjournals.org/lookup/volpage/48/1945?iss=12)*** ![Figure3](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F3.medium.gif) [Figure3](http://jnm.snmjournals.org/content/48/12/11A/F3) **Variable patient size and PET:** El Fakhri and colleagues assess whole-body 18F-FDG PET performance in lesion detection using a series of different acquisition and processing methods adjusted for patients of varying sizes and weights.
***[Page 1951](http://jnm.snmjournals.org/lookup/volpage/48/1951?iss=12)*** ![Figure4](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F4.medium.gif) [Figure4](http://jnm.snmjournals.org/content/48/12/11A/F4) **Metabolism vs. morphometry in AD:** Matsunari and colleagues compare the abilities of 18F-FDG PET and optimized voxel-based morphometry in discriminating between healthy individuals and those at progressive stages of Alzheimer's disease.
***[Page 1961](http://jnm.snmjournals.org/lookup/volpage/48/1961?iss=12)*** **11C-Met PET normal references:** Coope and colleagues describe coregistration methods to facilitate interpretation of 11C-methionine PET images with reference to averaged normal uptake maps, allowing standardization of analysis and increased sensitivity to tumor infiltration.
***[Page 1971](http://jnm.snmjournals.org/lookup/volpage/48/1971?iss=12)*** ![Figure5](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F5.medium.gif) [Figure5](http://jnm.snmjournals.org/content/48/12/11A/F5) **D2 receptors and iNPH:** Nakayama and colleagues use 11C-raclopride PET to extend their studies of idiopathic normal pressure hydrocephalus, focusing on treatment with ventriculoperitoneal shunts and the contributions of dopamine receptors to associated pathophysiology.
***[Page 1981](http://jnm.snmjournals.org/lookup/volpage/48/1981?iss=12)*** ![Figure6](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F6.medium.gif) [Figure6](http://jnm.snmjournals.org/content/48/12/11A/F6) **Microvascular resistance in chronic infarct areas:** Marques and colleagues report on an H215O PET study comparing fractional flow reserve in infarct-related arteries and reference flow reserve in patients with chronic myocardial infarction.
***[Page 1987](http://jnm.snmjournals.org/lookup/volpage/48/1987?iss=12)*** **Spironolactone and candesartan in CHF:** Kasama and colleagues investigate the effects of the angiotensin-receptor blocker candesartan alone and in combination with spironolactone in cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
***[Page 1993](http://jnm.snmjournals.org/lookup/volpage/48/1993?iss=12)*** **Nuclear imaging in CRT:** Henneman and colleagues provide an educational overview of the status of cardiac resynchronization therapy in heart failure, including a review of nuclear medicine techniques in initial assessment, evaluation of therapy, and prediction of outcomes.
***[Page 2001](http://jnm.snmjournals.org/lookup/volpage/48/2001?iss=12)*** ![Figure7](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F7.medium.gif) [Figure7](http://jnm.snmjournals.org/content/48/12/11A/F7) **Imaging mesenchymal stem cells:** Love and colleagues describe a triple-reporter system for bioluminescence and PET imaging to monitor human mesenchymal stem cell transplants and discuss the potential for translation to human studies with PET.
***[Page 2011](http://jnm.snmjournals.org/lookup/volpage/48/2011?iss=12)*** ![Figure8](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F8.medium.gif) [Figure8](http://jnm.snmjournals.org/content/48/12/11A/F8) **18F-F-CP PET for breast cancer:** Kesner and colleagues examine the biodistribution of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts and report on the potential of this technique in predicting the resistance of tumors to cyclophosphamide therapy.
***[Page 2021](http://jnm.snmjournals.org/lookup/volpage/48/2021?iss=12)*** ![Figure9](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F9.medium.gif) [Figure9](http://jnm.snmjournals.org/content/48/12/11A/F9) **Antisense imaging:** Liu and colleagues investigate whether a 99mTc-radiolabeled antisense oligonucleotide targeting human telomerase reverse transcriptase mRNA can be used for in vivo imaging of telomerase activity in carcinomas.
***[Page 2028](http://jnm.snmjournals.org/lookup/volpage/48/2028?iss=12)*** ![Figure10](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F10.medium.gif) [Figure10](http://jnm.snmjournals.org/content/48/12/11A/F10) **Math model of dynamic 18F-FDG PET data:** Ferl and colleagues report on a novel method for plasma time–activity curve estimation in murine small-animal PET studies, based on a model of tracer kinetics in blood, muscle, and liver.
***[Page 2037](http://jnm.snmjournals.org/lookup/volpage/48/2037?iss=12)*** **11C-lactate PET and myocardial imaging:** Herrero and colleagues use l-3-11C-lactate PET to acquire noninvasive quantitative measurements of myocardial lactate metabolism in animals.
***[Page 2046](http://jnm.snmjournals.org/lookup/volpage/48/2046?iss=12)*** ![Figure11](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F11.medium.gif) [Figure11](http://jnm.snmjournals.org/content/48/12/11A/F11) **Tracer uptake in brain abscesses:** Salber and colleagues compare uptake of the amino acid tracer 18F-FET with that of 3H-MET and 3H-DG in brain abscesses in rats to assess the suitability of 18F-FET imaging for distinguishing between inflammation and gliomas.
***[Page 2056](http://jnm.snmjournals.org/lookup/volpage/48/2056?iss=12)*** ![Figure12](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F12.medium.gif) [Figure12](http://jnm.snmjournals.org/content/48/12/11A/F12) **LAT-mediated amino acid uptake in tumors:** Haase and colleagues provide evidence that 18F-labeled amino acids that accumulate in tumors via system L amino acid transporters represent an important class of imaging agents for in vivo PET visualization of tumors.
***[Page 2063](http://jnm.snmjournals.org/lookup/volpage/48/2063?iss=12)*** **Radiation dosimetry of 11C-PBR28:** Brown and colleagues report on studies estimating human radiation doses for this recently developed radioligand, which shows promise in imaging peripheral benzodiazepine receptors.
***[Page 2072](http://jnm.snmjournals.org/lookup/volpage/48/2072?iss=12)*** **Radiation safety with 90Y-microspheres:** Gulec and Siegel describe radiation safety issues associated with the intrahepatic arterial administration of 90Y-resin or 90Y-glass microspheres, including dose estimates and posttherapy management.
***[Page 2080](http://jnm.snmjournals.org/lookup/volpage/48/2080?iss=12)*** #### ON THE COVER This schematic for the noninvasive imaging of stem cell fate in myocardium shows the 4 different techniques currently in use for tracking stell cells in vivo, including magnetic particle labeling, radionuclide labeling, quantum dot labeling, and reporter gene labeling. ![Figure13](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F13.medium.gif) [Figure13](http://jnm.snmjournals.org/content/48/12/11A/F13) See page [1917](http://jnm.snmjournals.org/lookup/volpage/48/1916?iss=12).